Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WBC100 in Advanced Solid Tumors
NCT05100251Phase 1Terminated
- Sponsor
- Zhejiang University
- Start
- Dec 2021
- Primary completion
- Jan 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of WBC100 in solid tumor and pancreatic cancer (PC) (3 arms), sponsored by Zhejiang University. Primary endpoints: Frequency of Adverse Event and Severe Adverse Event at 2 years, Dose limited toxicity at 28 days and 1 more. Started Dec 2021; status: terminated.
02
Drugs
WBC100
03
Conditions
solid tumorpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05100251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05100251.